Fig. 2. Effect of nitric oxide synthase (NOS) blockers on CO-releasing molecule (CORM)-induced IBK activation. (A) Summarized current–voltage (I–V) curves for the effects of CORM-2 or CORM-3 after L-N^G-monomethyl arginine citrate (L-NMMA, an NOS blocker, 100 μM) pre-treatments. IBK was confirmed by 10 μM paxilline. (B) Bar graphs show the summary of the current density changes regarding the effects of CORM-2 or CORM-3 (10 μM, each) after L-NMMA (100 μM) pre-treatments at +50 mV. ***p < 0.001 paxilline vs. control (n = 10, each). (C) Summarized I–V curves for the effects of CORM-2 or CORM-3 after L-N^G-nitroarginine methyl ester (L-NAME, an NOS blocker, 100 μM) pre-treatments. (D) Bar graphs showing the summary of the current density changes regarding the effects of CORM-2 or CORM-3 after L-NAME pre-treatments at +50 mV (n = 12, each).

Korean J Physiol Pharmacol 2021;25:227-237 https://doi.org/10.4196/kjpp.2021.25.3.227

© Korean J Physiol Pharmacol